1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.
Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 4, 4, 3 and 1 respectively.
Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Acromegaly - Therapeutics Development
Acromegaly - Therapeutics Assessment
Acromegaly - Companies Involved in Therapeutics Development
atesidorsen sodium - Drug Profile
DP-2018 - Drug Profile
FP-002 - Drug Profile
IONIS-GHRLRx - Drug Profile
ITF-2984 - Drug Profile
lanreotide SR - Drug Profile
MOD-12014 - Drug Profile
octreotide - Drug Profile
octreotide acetate - Drug Profile
octreotide acetate - Drug Profile
octreotide acetate CR - Drug Profile
octreotide acetate DR - Drug Profile
octreotide acetate microspheres - Drug Profile
octreotide LA - Drug Profile
octreotide LA - Drug Profile
octreotide SR - Drug Profile
paltusotine - Drug Profile
Somadex - Drug Profile
Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
veldoreotide ER - Drug Profile
veldoreotide IR - Drug Profile
Acromegaly - Product Development Milestones
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Antisense Therapeutics Ltd
- Aquestive Therapeutics Inc
- Ascil Proyectos SL
- Auritec Pharmaceuticals Inc
- Camurus AB
- Chiasma Inc
- Crinetics Pharmaceuticals Inc
- Daewoong Pharmaceutical Co Ltd
- Dauntless Pharmaceuticals Inc
- DexTech Medical AB
- Enesi Pharma Ltd
- Foresee Pharmaceuticals Co Ltd
- GeneScience Pharmaceuticals Co Ltd
- GlyTech Inc
- Ionis Pharmaceuticals Inc
- Italfarmaco SpA
- OPKO Health Inc
- Pharmathen Global BV
- Strongbridge Biopharma plc